**S6 Table. Primary and secondary efficacy criteria at 6 months post injection (Full Analysis Set).**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Outcome** | **SH**n = 139 | **Control**n = 141 | **Difference** | ***P*** |
| WOMAC A change from baseline (mm) |  |  |  |  |
| Mean (SE) | -33.3 (1.7) | -36.1 (1.9) | -2.8 (1.9) | 0.3† |
| 95% CI | (-36.7, -29.8) | (-39.8, -32.4) | (-7.9, 2.2) |  |
| WOMAC B change from baseline (mm) |  |  |  |  |
| Mean (SE) | -21.9 (2.1) | -26.9 (1.9) | -5.0 (2.9) | 0.08† |
| 95% CI | (-26.1, -17.7) | (-30.7, -23.1) | (-10.7, 0.6) |  |
| WOMAC C change from baseline (mm) |  |  |  |  |
| Mean (SE) | -21.3 (1.6) | -26.1 (1.8) | -4.9 (2.4) | 0.04† |
| 95% CI | (-24.4, -18.1) | (-29.6, -22.6) | (-9.5, 0.1) |  |
| Lequesne index change from baseline |  |  |  |  |
| Mean (SE) | -4.2 (0.3) | -4.7 (0.4) | -0.5 (0.5) | 0.3† |
| 95% CI | (-4.8, -3.6) | (-5.4, -4.0) | (-1.4, 0.4) |  |
| PtGA change from baseline (mm) |  |  |  |  |
| Mean (SE) | -24.0 (2.1) | -27.3 (2.0) | -3.3 (2.9) | 0.3† |
| 95% CI | (-28.1, -19.9) | (-31.3, -23.4) | (-9.0, 2.3) |  |
| Global treatment efficacy (good/very good), n (%) |  |  |  |  |
| By the patient | 86 (64.7) | 84 (64.1) |  | >0.9‡ |
| By the investigator | 90 (67.7) | 87 (66.4) |  | 0.9‡ |
| Acetaminophen use post injection (yes), n (%) | 101 (72.7) | 97 (68.8) |  | 0.5‡ |
| OMERACT-OARSI responders, n (%) | 107 (81.1) | 113 (86.3) |  | 0.3§ |

† Student’s t-test;‡ Fisher’s exact test; § Chi-square test.

CI = confidence interval; control = hylan G-F 20; OMERACT-OARSI = Outcome Measures in Rheumatoid Arthritis Clinical Trials - Osteoarthritis Research Society International; PtGA = patient global assessment of disease activity; SE = standard error; SH = sodium hyaluronate; WOMAC A, B, C = Western Ontario and McMaster Universities Osteoarthritis Index pain, stiffness, function subscales, respectively.